Quilizumab
Quilizumab
Quilizumab (pronunciation: kwi-liz-u-mab) is a monoclonal antibody designed for the treatment of asthma and allergic diseases. It was developed by Genentech, a member of the Roche Group.
Etymology
The name "Quilizumab" is derived from the International Nonproprietary Names (INN), where "zu" refers to humanized antibody, "li" indicates immunomodulating, and "mab" is the suffix for monoclonal antibodies.
Mechanism of Action
Quilizumab targets the M1-prime segment of membrane-expressed IgE, leading to the depletion of IgE-switched and memory B cells. By doing so, it reduces the levels of circulating IgE, which plays a crucial role in the pathogenesis of allergic diseases.
Clinical Trials
Quilizumab has undergone Phase II clinical trials for the treatment of allergic rhinitis and uncontrolled asthma. However, the development was discontinued after the trials due to its insufficient efficacy.
Related Terms
External links
- Medical encyclopedia article on Quilizumab
- Wikipedia's article - Quilizumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski